*****[+]

Approved for use through 10/31/2002. OMB 0651-0031*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Pap	erwork Red	uction Act of 1995, no person	is are required to respond to a collection.	of information unless it contains a valid OMB control number				
Substitute	for form 1449A				Complete if Known				
	D144710			Application Number	TEX 10/10/8089				
			SCLOSURE	Filing Date	Herewith				
STAT	EMENT	BY A	PPLICANT	First Named Inventor	Arsinur Borcoglu				
•				Group Art Unit	1633 1/32				
(use as many	sheets a	s necessary)	Examiner Name	Shin-Lin Chen				
Sheet	1	of	2	Attorney Docket Number	2939.00003				

		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DOCUM	MENTS	
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		(if known)		MM-DD-YYYY ·	Figures Appear
4re		3,770,720	Butti, et al.	. 11/6/73	
		3,899,481	Butti, et al.	8/12/75	
		5,449,616	Campbell, et al.	9/12/95	
		5,556,772	Sorge, et al.	9/17/96	
		5,081,109	Ulutin	1/14/92	
		4,693,995	Prino, et al.	9/15/87	
5V.		4,649,134	Bonomini	3/10/87	
					
				· · · · · · · · · · · · · · · · · · ·	
		 			
		 		·	
				·	
		 	 		
		 			

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
		Office ³	Number	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т ₆
4m		PCT	Wo 94/15621			7/21/94		
		 						
	_			_				

|--|

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) Inside this box	+
---	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known				
INEOE	AA A TION	I DICC	CLOSURE	Application Number	TRA .	_		
				Filing Date	TBA	_		
STATEMENT BY APPLICANT				First Named Inventor	Arsinur Burcoglu			
				Group Art Unit		_		
	ıse as many sı	heets as n	ecessary)	Examiner Name				
Sheet	2	of	2	Attorney Docket Number	002939.00003	ブ		

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Mastrangelo et al., Seminars in Oncology, Vol. 23(1), p. 4-21., 2/96 Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy,12/95 Franzpeter Bracht and Karsten Schorr, Biochemical and Biophysical Research Communications, Vol. 200(2) 933-937, 4/94 Bracht, et al., "Isolation and Identification of Aptamers from Defibrotide that Act as Thrombin Antagonists In Vitro," Biochem. & Biophys Res. Comm., 200(2):933-937 (1994) Harrison's PRINCIPLES OF INTERNAL MEDICINE, 10th edition, Patersdof et al. Eds. McGraw Hill	Τ2
Orkin et al., Report and Recommendations of the Panel to Assess the NiH Investment in Research on Gene Therapy,12/95 Franzpeter Bracht and Karsten Schorr, Biochemical and Biophysical Research Communications, Vol. 200(2) 933- 937, 4/94 Bracht, et al., "Isolation and Identification of Aptamers from Defibrotide that Act as Thrombin Antagonists In Vitro," Blochem. & Biophys Res. Comm., 200(2):933-937 (1994)	
Therapy,12/95 Franzpeter Bracht and Karsten Schorr, Biochemical and Biophysical Research Communications, Vol. 200(2) 933-937, 4/94 Bracht, et al., "Isolation and Identification of Aptamers from Defibrotide that Act as Thrombin Antagonists In Vitro," Blochem. & Biophys Res. Comm., 200(2):933-937 (1994)	
937, 4/94 Bracht, et al., "Isolation and Identification of Aptamers from Defibrotide that Act as Thrombin Antagonists in Vitro," Blochem. & Biophys Res. Comm., 200(2):933-937 (1994)	
Blochem. & Biophys Res. Comm., 200(2):933-937 (1994)	
Harrison's PRINCIPLES OF INTERNAL MEDICINE, 18 th edition, Petersdof et al. Eds., McGrew Hill	
Horn et al., Plant Physiol, 1990, 93:1492-1496	
Leonetti et al., Bioconjugate Chem., 1990, 1:149-153	
Nolka and Pollard, 1992, Aids Research and Human Retroviruses 8(7):1225-1261	
Ross, 1992, Current Biology, 2(10):517-519	
Sarin et al., Proc. Natl Acad. Sci. U.S.A., 1988, 85:7448-7451	
	Notka and Pollard, 1992, Aids Research and Human Retroviruses 8(7):1225-1261 Ross, 1992, Current Biology, 2(10):517-519

00.00.00	Examiner Signature	Shin-Lin.	//////////////////////////////////////	Date Considered	10-14-07
----------	-----------------------	-----------	--	--------------------	----------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.